文献速递儿童消化与营养儿童感染

不同配方对牛奶蛋白过敏患儿特应性表现及免疫耐受的影响

The Impact of Formula Choice for the Management of Pediatric Cow's Milk Allergy on the Occurrence of Other Allergic Manifestations: The Atopic March Cohort Study.
PubMed 文献 · J Pediatr · 2021-01-29

这项36个月前瞻性队列研究纳入365名IgE介导的牛奶蛋白过敏儿童,每队列73人,比较五种配方对特应性表现发生率和免疫耐受获得时间的影响。结果显示,含鼠李糖乳杆菌GG的深度水解酪蛋白配方组特应性表现发生率最低(0.22),其他配方组均更高,且该组36个月免疫耐受获得率更高。

要点

  • 含鼠李糖乳杆菌GG的深度水解酪蛋白配方组特应性表现发生率0.22,其他配方组为0.51–0.77。
  • 含鼠李糖乳杆菌GG的深度水解酪蛋白配方组36个月免疫耐受获得率更高。

核心结论

  • 使用含鼠李糖乳杆菌GG的深度水解酪蛋白配方治疗牛奶蛋白过敏与较低的特应性表现发生率和较高的免疫耐受获得率相关。

研究设计与样本

  • 36个月前瞻性队列研究,纳入365名IgE介导的牛奶蛋白过敏儿童,每配方队列73人。

主要发现

  • 特应性表现发生率:含鼠李糖乳杆菌GG的深度水解酪蛋白配方组0.22(Bonferroni校正95%CI 0.09-0.34),大米水解配方组0.52(0.37-0.67),大豆配方组0.58(0.43-0.72),深度水解乳清配方组0.51(0.36-0.66),氨基酸配方组0.77(0.64-0.89)。

关键数值与推荐

  • 大米水解配方 vs 含鼠李糖乳杆菌GG的深度水解酪蛋白配方风险比2.37(1.46-3.86,P<.001)。
  • 大豆配方 vs 含鼠李糖乳杆菌GG的深度水解酪蛋白配方风险比2.62(1.63-4.22,P<.001)。
  • 深度水解乳清配方 vs 含鼠李糖乳杆菌GG的深度水解酪蛋白配方风险比2.31(1.42-3.77,P<.001)。
  • 氨基酸配方 vs 含鼠李糖乳杆菌GG的深度水解酪蛋白配方风险比3.50(2.23-5.49,P<.001)。

临床怎么用

  • 对IgE介导的牛奶蛋白过敏患儿,选择含鼠李糖乳杆菌GG的深度水解酪蛋白配方可能降低其他特应性表现发生风险并提高免疫耐受获得率。

局限性

  • 原文摘要未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To compare the impact of different formulas on the occurrence of other atopic manifestations and the time of immune tolerance acquisition. STUDY DESIGN: In a 36-month prospective cohort study, the occurrence of other atopic manifestations (eczema, urticaria, asthma, and rhinoconjunctivitis) and the time of immune tolerance acquisition were comparatively evaluated in immunoglobulin E-mediated children with cow's milk allergy (CMA) treated with extensively hydrolyzed casein formula containing the probiotic L. rhamnosus GG (EHCF + LGG), rice hydrolyzed formula, soy formula, extensively hydrolyzed whey formula (EHWF), or amino acid-based formula. RESULTS: In total, 365 subjects were enrolled into the study, 73 per formula cohort. The incidence of atopic manifestations was 0.22 (Bonferroni-corrected 95% CI 0.09-0.34) in the EHCF + LGG cohort; 0.52 (0.37-0.67) in the rice hydrolyzed formula cohort; 0.58 (0.43-0.72) in the soy formula cohort; 0.51 (0.36-0.66) in the EHWF cohort; and 0.77 (0.64-0.89) in the amino acid-based formula cohort. The incidence of atopic manifestations in the rice hydrolyzed formula, soy formula, EHWF, and amino acid-based formula cohorts vs the EHCF + LGG cohort was always greater than the prespecified absolute difference of 0.25 at an alpha-level of 0.0125, with corresponding risk ratios of 2.37 (1.46-3.86, P < .001) for rice hydrolyzed formula vs EHCF + LGG; 2.62 (1.63-4.22, P < .001) for soy formula vs EHCF + LGG; 2.31 (1.42-3.77, P < .001) for EHWF vs EHCF + LGG; and 3.50 (2.23-5.49, P < .001) for amino acid-based formula vs EHCF + LGG. The 36-month immune tolerance acquisition rate was greater in the EHCF + LGG cohort. CONCLUSIONS: The use of EHCF + LGG for CMA treatment is associated with lower incidence of atopic manifestations and greater rate of immune tolerance acquisition.

来源:J Pediatr,查看原文。版权归原作者所有。

引用

  1. Nocerino R, Bedogni G, Carucci L, et al. The Impact of Formula Choice for the Management of Pediatric Cow's Milk Allergy on the Occurrence of Other Allergic Manifestations: The Atopic March Cohort Study. J Pediatr. 2021. PMID: 33524387. doi:10.1016/j.jpeds.2021.01.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。